Objectives: To evaluate the in vivo antibacterial efficacy of chinfloxacin, a novel fluoroquinolone, in murine systemic and local infection models.
Introduction
Chinfloxacin is a new synthetic fourth-generation fluoroquinolone and has a structure similar to that of moxifloxacin except for difluoride substitution in the 8-methoxy group. In vitro activity studies demonstrated that chinfloxacin had activity comparable to that of moxifloxacin, 2 -16-fold higher activity than ciprofloxacin and levofloxacin against Gram-positive isolates and similar to or 2 -8-fold lower activity than ciprofloxacin and levofloxacin against Gram-negative isolates. Studies by Zhang et al.
1 demonstrated that the IC 50 of chinfloxacin for inhibition of the open state HERG K + channel was 2-fold higher than that of moxifloxacin, indicating cardiac toxicity possibly lower than that of moxifloxacin. In this study, the efficacy of chinfloxacin was further evaluated in vivo in mouse systemic and local infection models. 
Materials and methods

Antimicrobial agents
Mouse systemic infection model
The in vivo therapeutic efficacies of chinfloxacin and the comparators moxifloxacin and levofloxacin in the mouse systemic infection model were assessed with four strains of S. aureus, three strains of S. pneumoniae, three strains of E. faecalis, three strains of E. coli and two strains of K. pneumoniae (Table 1 ). The experiment was carried out by a method from the literature with modifications. 2 For each isolate infection, 160 CD-1 ICR mice (body weight, 18-21 g) were allocated randomly to 16 groups, with 5 groups (5 doses) for each compound and 1 control group (10 mice per group, 5 males and 5 females). The mice were infected intraperitoneally with 0.5 mL of a bacterial suspension in 5% mucin (100% minimal lethal dose). At 15 min and 6 h after challenge, five dose levels of each compound were administered orally. The dose ranges of chinfloxacin were 1.6-4.0, 3.0-6.0, 3.0-6.0 and 2.5-30.0 mg/kg for S. aureus ATCC 29213, 0605, 0629 and 0910 infections, respectively; 5.0-12.6, 1.9-4.8 and 2.6-8.0 mg/kg for S. pneumoniae ATCC 49619, 0518 and 0613 infections, respectively; 20.0 -50.0, 10.0 -20.0 and 5.0-40.0 mg/kg for E. faecalis ATCC 29212, ATCC 700802 and ATCC 51575 infections, respectively; 1.0-2.5, 0.8-1.6 and 1.27 -3.2 mg/kg for E. coli ATCC 25922, 0635 and 0638 infections, respectively; and 5.0-12.6 and 1.9-4.8 mg/kg for K. pneumoniae 0548 and 0613 infections, respectively. Mortality in each group was recorded daily for 7 days, and the 50% effective dose (ED 50 ) and 95% confidence limits were determined by probit analysis. 3 
Mouse pulmonary infection model
The therapeutic efficacies of chinfloxacin and moxifloxacin, levofloxacin and ciprofloxacin in mouse pulmonary infections caused by S. pneumoniae ATCC 6301 (PSSP), S. pneumoniae 0062 (PRSP), K. pneumoniae 9613 and K. pneumoniae 7 were evaluated with female CD-1 ICR mice (body weight 20-22 g; 10 mice per group) by published methods with modifications. 4, 5 The mice were anaesthetized with pentobarbital sodium at 50 mg/kg and infected intranasally with 50 mL of fresh bacterial suspension in saline (challenge dose 7.3×10 6 cfu/mouse for S. pneumoniae ATCC 6301, 6.5×10 6 cfu/mouse for S. pneumoniae 0062, 2.5×10 7 cfu/mouse for K. pneumoniae 9613 and 2.3×10 6 cfu/mouse for K. pneumoniae 7). Four different doses of chinfloxacin (12.5, 25, 50 and 100 mg/kg) and the reference compounds moxifloxacin, levofloxacin and ciprofloxacin were administered orally 6 h after infection (administration at one timepoint). The mice were sacrificed 24 h after infection and the lungs were removed aseptically. The lungs were homogenized in saline (0.1 g tissue in a final volume of 1 mL), viable colony counts were determined by spreading 0.1 mL of properly diluted homogenates onto nutrient agar (for K. pneumoniae) or blood agar (MH agar with 5% sheep blood for S. pneumoniae) plates and incubated at 358C for 24 h (in a 5% CO 2 environment for S. pneumoniae). The lower detection limit was 2 log (cfu/g), which corresponded to the weakest dilution of lung tissue that avoided significant drug carryover (10 21 ). Statistical significance was determined using SPSS 12.0. 6 .20 mg/kg), S. pneumoniae 0518 (PRSP, ED 50 3.51 mg/kg) and S. pneumoniae 0613 (PRSP, ED 50 5.03 mg/kg), which was comparable to that of moxifloxacin (ED 50 4.59, 2.99 and 4.27 mg/kg, respectively), but significantly higher (P,0.05 or P,0.01) than that of levofloxacin (ED 50 13.14, 15.80 and 18.06 mg/kg, respectively). The ED 50 s of chinfloxacin against E. faecalis ATCC 29212 (VSE), E. faecalis ATCC 700802 (VRE) and E. faecalis ATCC 51575 (VRE) infections (25.02, 15.39 and 5.18 mg/kg, respectively) were similar to those of moxifloxacin, but significantly lower than those of levofloxacin (P,0.01 or P,0.05). The therapeutic efficacy of chinfloxacin against Gram-negative isolate infections (E. coli and K. pneumoniae) was high, with ED 50 s in the range of 1.25 -1.90 mg/kg for E. coli and 2.92 -8.28 mg/kg for K. pneumoniae. The efficacy of chinfloxacin against these isolates was generally comparable to (P .0.05) that of moxifloxacin (ED 50 1.13 -1.60 mg/kg for E. coli and 2.35-7.29 mg/kg for K. pneumoniae) and significantly lower (P, 0.01) than that of levofloxacin (ED 50 0.53-0.97 mg/kg for E. coli and 0.72-3.29 mg/kg for K. pneumoniae).
Results
Mouse systemic infection model
Mouse pulmonary infection model
The in vivo activity of chinfloxacin and the reference compounds in mouse pulmonary infections caused by S. pneumoniae and K. pneumoniae are shown in Table 2 . Chinfloxacin and the reference compounds exhibited dose-dependent colony-count-lowering efficacy in mouse lung infections with tested S. pneumoniae and K. pneumoniae isolates, the lung colony counts being significantly Li et al. MICs were determined by the agar dilution method according to CLSI recommendations. In vivo activity of chinfloxacin 
